Inj irinotecan liposome 1 mg
Products billed under this code include Onivyde.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Onivyde.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Onivyde | Ipsen Biopharmaceuticals, Inc. | 15054-0043-01 | 43 | $2,874.808 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $66.856 | +$0.995 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $65.861 | −$0.513 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $66.374 | +$0.418 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $65.956 | −$0.043 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $65.999 | +$0.744 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $65.255 | −$0.023 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $65.278 | +$1.063 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $64.215 | −$0.55 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $64.765 | +$1.39 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $63.375 | −$0.068 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $63.443 | +$1.423 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $62.02 | −$0.465 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $62.485 | +$0.521 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $61.964 | +$2.014 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $59.95 | −$0.112 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $60.062 | +$0.017 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $60.045 | −$0.095 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $60.14 | +$2.628 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $57.512 | +$0.141 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $57.371 | +$0.175 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $57.196 | +$0.591 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $56.605 | +$2.377 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $54.228 | −$0.079 | 1 MG | Inj irinotecan liposome 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $54.307 | – | 1 MG | Inj irinotecan liposome 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.